Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AK117 |
Synonyms | |
Therapy Description |
AK117 is a monoclonal antibody that binds CD47, potentially resulting in decreased tumor growth (Journal for ImmunoTherapy of Cancer 2020;8). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AK117 | AK 117|AK-117|Ligufalimab | CD47 Antibody 31 | AK117 is a monoclonal antibody that binds CD47, potentially resulting in decreased tumor growth (Journal for ImmunoTherapy of Cancer 2020;8). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04349969 | Phase I | AK117 | Phase 1, Dose Escalation and Dose Expansion Study of AK117, a CD47-targeting Antibody | Completed | AUS | 0 |